Rapid reduction of adenomyosis coexisting with leiomyoma volume during treatment with Relugolix

Rapid reduction of adenomyosis coexisting with leiomyoma volume during treatment with Relugolix

Objective This study elucidated the efficacy of Relugolix (REL) on the reduction of uterine volume and clinical symptoms for the treatment of adenomyosis.Methods We conducted a retrospective cohort study of patients who received REL (40 mg for about 20 weeks) and who underwent a hysterectomy for ade...

ver descrição completa

Detalhes bibliográficos
Main Authors:	Keitaro Yamanaka, Keiichi Washio, Akiko Uchida, Yuki Sasagawa, Masashi Nishimoto, Yui Yamasaki, Satoshi Nagamata, Yoshito Terai
Formato:	Artigo
Idioma:	English
Publicado em:	Taylor & Francis Group 2023-12-01
Colecção:	Gynecological Endocrinology
Assuntos:	Adenomyosis relugolix fibroids GnRH antagonist GnRH agonist
Acesso em linha:	https://www.tandfonline.com/doi/10.1080/09513590.2023.2237121

Registos relacionados

A case of adenomyosis with leiomyoma that was effectively treated with relugolix and kamishoyosan add-on therapy
Por: Yukifumi Sasamori, et al.
Publicado em: (2021-08-01)

An Efficient UPLC-MS/MS Method Established to Detect Relugolix Concentration in Rat Plasma
Por: Liying Xing, et al.
Publicado em: (2022-06-01)

The clinical trial of alternative relugolix administration for uterine leiomyoma prior to surgically treatment: a study protocol for Non-Adverse Relugolix Administration (NARA) trial
Por: Naoki Kawahara, et al.
Publicado em: (2024-01-01)

Comparison of pregnancy outcomes between GnRH antagonist protocol with freeze-all strategy and long-acting GnRH agonist protocol in women with adenomyosis undergoing IVF/ICSI: a propensity-score matching analysis
Por: Liting Zhang, et al.
Publicado em: (2022-12-01)

GnRH agonist versus GnRH antagonist in <it>in vitro</it> fertilization and embryo transfer (IVF/ET)
Por: Depalo Raffaella, et al.
Publicado em: (2012-04-01)

Ultrasonographic Evaluation of the Change in Uterine Fibroids Induced by Treatment with a Gnrh Analog
Por: Chun-Chieh Chia, et al.
Publicado em: (2006-06-01)

Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis
Por: Juan C. Arjona Ferreira, M.D., et al.
Publicado em: (2023-06-01)

GnRH antagonist versus agonist in normoresponders undergoing ICSI: a randomized clinical trial in Iran
Por: Ensieh Tehraninejad, et al.
Publicado em: (2011-01-01)

GnRH agonist for final oocyte maturation in GnRH antagonist co-treated IVF/ICSI treatment cycles: Systematic review and meta-analysis
Por: M.A.F. Youssef, et al.
Publicado em: (2015-05-01)

Recent Development of Non-Peptide GnRH Antagonists
Por: Feng-Ling Tukun, et al.
Publicado em: (2017-12-01)

Clinical efficacy and safety of trimonthly administration of goserelin acetate 10.8 mg in premenopausal Chinese females with symptomatic adenomyosis: a prospective cohort study
Por: Hao Sun, et al.
Publicado em: (2023-12-01)

Ultra-Long GnRH Agonist Protocol During IVF/ICSI Improves Pregnancy Outcomes in Women With Adenomyosis: A Retrospective Cohort Study
Por: Jie Lan, et al.
Publicado em: (2021-05-01)

Neurobiological study of fish brains gives insights into the nature of Gonadotropin-releasing hormone 1-3 neurons.
Por: Tomomi eKarigo, et al.
Publicado em: (2013-11-01)

GnRH Induces ERK-Dependent Bleb Formation in Gonadotrope Cells, Involving Recruitment of Members of a GnRH Receptor-Associated Signalosome to the Blebs
Por: Liat Rahamim-Ben Navi, et al.
Publicado em: (2017-06-01)

Efficacy and uterine bleeding patterns in initiating goserelin therapy during different menstrual phases in patients with adenomyosis: a prospective cohort study
Por: Ying Lin, et al.
Publicado em: (2024-12-01)

Protocolo largo con análogos de GnRH versus protocolo corto con antagonistas: ¿existen diferencias en cuanto a los resultados de los ciclos de FIV-ICSI?
Por: Laura Blasco G, et al.
Publicado em: (2011-01-01)

Comparison of Controlled Ovarian Stimulation Protocols on IVF Outcome in Normal and Poor Responders
Por: Deniz Esinler, et al.
Publicado em: (2013-12-01)

Clinical applications of gonadotropin-releasing hormone analogues: a broad impact on reproductive medicine
Por: Farrah L. Saleh, M.D., et al.
Publicado em: (2023-06-01)

Use of gonadotropin-releasing hormone (GnRH) agonist trigger in fertility preservation for patients with inherited genetic disorders
Por: Jamie Merkison, et al.
Publicado em: (2022-09-01)

GnRH agonists to sustain the luteal phase in antagonist IVF cycles: a randomized prospective trial
Por: Francesco M. Fusi, et al.
Publicado em: (2019-11-01)

GnRH agonist improves pregnancy outcome in mice with induced adenomyosis by restoring endometrial receptivity
Por: Guo S, et al.
Publicado em: (2018-06-01)

Transcriptome analysis of endometrial tissues following GnRH agonist treatment in a mouse adenomyosis model
Por: Guo S, et al.
Publicado em: (2017-03-01)

Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix
Por: Kristof Chwalisz, M.D., Ph.D.
Publicado em: (2023-06-01)

Comparison of pregnancy outcome after fresh embryo transfer between GnRH antagonist and GnRH agonist regimens in patients with thin endometrium
Por: Depeng Zhao, et al.
Publicado em: (2023-01-01)

OVARIAN STIMULATION FOR IVF-ET PROCEDURE
Por: Robert Medved, et al.
Publicado em: (2002-03-01)

Editorial: Gonadotropin-Releasing Hormone Receptor Signaling and Functions
Por: Ivana Bjelobaba, et al.
Publicado em: (2018-04-01)

GnRH pulse generator activity in mouse models of polycystic ovary syndrome
Por: Ziyue Zhou, et al.
Publicado em: (2025-01-01)

Effect of triptorelin on lower urinary tract symptoms in Australian prostate cancer patients
Por: Woo HH, et al.
Publicado em: (2017-02-01)

Comparison of the treatment efficacies of HIFU, HIFU combined with GnRH-a, and HIFU combined with GnRH-a and LNG-IUS for adenomyosis: A systematic review and meta-analysis
Por: Altangerel Otgontuya, et al.
Publicado em: (2023-03-01)

Immunohistochemical evaluation of leiomyoma tissue and normal myometrium in patients with uter-ine leiomyoma during hypo- and hyperestrogenic conditions caused by of use of gonadotropin-releasing hormone ana-logues
Por: Medvedev M.V.
Publicado em: (2012-01-01)

A Validated Model for Individualized Prediction of Live Birth in Patients With Adenomyosis Undergoing Frozen–Thawed Embryo Transfer
Por: Yaoqiu Wu, et al.
Publicado em: (2022-05-01)

Progesterone change in the late follicular phase affects pregnancy rates both agonist and antagonist protocols in normoresponders: a case-controlled study in ICSI cycles
Por: Berfu Demir, et al.
Publicado em: (2016-05-01)

GnRH Vaccine Could Suppress Serum Testosterone in Stallion Mules
Por: Siriporn Khumsap, et al.
Publicado em: (2024-06-01)

Intraindividual Embryo Morphokinetics Are Not Affected by a Switch of the Ovarian Stimulation Protocol Between GnRH Agonist vs. Antagonist Regimens in Consecutive Cycles
Por: Jens E. Dietrich, et al.
Publicado em: (2020-04-01)

Protocol shift from agonist to antagonist or vice versa after an unsuccessful intracytoplasmic sperm injection cycle on the same patient does not improve outcome
Por: Yavuz Emre Şükür, et al.
Publicado em: (2018-06-01)

Patients With Deep Ovarian Suppression Following GnRH Agonist Long Protocol May Benefit From a Modified GnRH Antagonist Protocol: A Retrospective Cohort Study
Por: Shan Liu, et al.
Publicado em: (2021-07-01)

Effects of duration of long-acting GnRH agonist downregulation on assisted reproductive technology outcomes in patients with adenomyosis: a retrospective cohort study
Por: Yexing Li, et al.
Publicado em: (2023-09-01)

Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs
Por: Maira Huerta-Reyes, et al.
Publicado em: (2019-10-01)

Morphological Evidence for Functional Crosstalk Between Multiple GnRH Systems in the Male Tilapia, Oreochromis niloticus
Por: Satoshi Ogawa, et al.
Publicado em: (2020-09-01)

The role of GnRH metabolite, GnRH-(1-5), in endometrial cancer
Por: Madelaine J. Cho-Clark, et al.
Publicado em: (2023-04-01)